To determine the mechanism by which GA sensitized pancreatic cancer cells to gemcitabine through inhibition of the ERK/E2F1/RRM2 pathway in vivo, IHC analysis was performed in the tumor tissues of the four experimental groups. Here, RRM2 is linked to pancreatic neoplasm.